This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!
Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log in
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jul 7;66(26):687-691.
doi: 10.15585/mmwr.mm6626a2.

Babesiosis Surveillance - Wisconsin, 2001-2015

Babesiosis Surveillance - Wisconsin, 2001-2015

Elizabeth Stein et al. MMWR Morb Mortal Wkly Rep. .

Abstract

Babesiosis is an emerging zoonotic disease caused primarily by Babesia microti, an intraerythocytic protozoan. Babesia microti, like the causal agents for Lyme disease and anaplasmosis, is endemic to the northeastern and upper midwestern United States where it is usually transmitted by the blacklegged tick, Ixodes scapularis. Although babesiosis is usually a mild to moderate illness, older or immunocompromised persons can develop a serious malaria-like illness that can be fatal without prompt treatment. The most common initial clinical signs and symptoms of babesiosis (fever, fatigue, chills, and diaphoresis) are nonspecific and present diagnostic challenges that can contribute to delays in diagnosis and effective treatment with atovaquone and azithromycin (1). Results of one study revealed a mean delay of 12-14 days from symptom onset to treatment (2). Knowledge of the incidence and geographic distribution of babesiosis can raise the index of clinical suspicion and facilitate more prompt diagnosis and lifesaving treatment (1). The first known case of babesiosis in Wisconsin was detected in 1985 (3), and babesiosis became officially reportable in the state in 2001. Wisconsin babesiosis surveillance data for 2001-2015 were analyzed in 3-year intervals to compare demographic, epidemiologic, and laboratory features among patients with cases of reported babesiosis. To determine possible reasons for an increase in reported Babesia infection, trends in electronic laboratory reporting and diagnosis by polymerase chain reaction testing (PCR) were examined. Between the first and last 3-year analysis intervals, there was a 26-fold increase in the incidence of confirmed babesiosis, in addition to geographic expansion. These trends might be generalizable to other states with endemic disease, similar suburbanization and forest fragmentation patterns, and warming average temperatures (4). Accurate surveillance in states where babesiosis is endemic is necessary to estimate the increasing burden of babesiosis and other tickborne diseases and to develop appropriate public health interventions for prevention and practice.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: No conflicts of interest were reported.

Figures

FIGURE 1
FIGURE 1
Total confirmed babesiosis case counts (N = 294) initially reported directly and electronically through the Wisconsin Electronic Disease Surveillance System (WEDSS), Electronic Laboratory Report (ELR) — Wisconsin, 2001–2015 *The WEDSS system records each case report’s first contact source. For example, if a health department or provider notified the Department of Public Health of a case of babesiosis and an electronic report followed, the source would not be categorized as ELR.
FIGURE 2
FIGURE 2
Geographic distribution of confirmed cases of babesiosis per 100,000 residents by county of residence — Wisconsin, 2001–2005, 2006–2010, and 2011–2015 * Twenty counties (28% of all Wisconsin counties) reported at least one confirmed babesiosis case during 2001–2005. During 2006–2010, the number of counties reporting more than one case increased to 30. During 2011–2015, the number of counties reporting more than one confirmed case increased to 46.

References

    1. Vannier EG, Diuk-Wasser MA, Ben Mamoun C, Krause PJ. Babesiosis. Infect Dis Clin North Am 2015;29:357–70 .10.1016/j.idc.201502008 - DOI - PMC - PubMed
    1. White DJ, Talarico J, Chang HG, Birkhead GS, Heimberger T, Morse DL. Human babesiosis in New York State: Review of 139 hospitalized cases and analysis of prognostic factors. Arch Intern Med 1998;158:2149–54 .10.1001/archinte.158.19.2149 - DOI - PubMed
    1. Steketee RW, Eckman MR, Burgess EC, et al. Babesiosis in Wisconsin. A new focus of disease transmission. JAMA 1985;253:2675–8 .10.1001/jama.1985.03350420087023 - DOI - PubMed
    1. Robinson SJ, Neitzel DF, Moen RA, et al. Disease risk in a dynamic environment: the spread of tick-borne pathogens in Minnesota, USA. Ecohealth 2015;12:152–63 .10.1007/s10393-014-0979-y - DOI - PMC - PubMed
    1. Leiby DA. Transfusion-transmitted Babesia spp.: bull’s-eye on Babesia microti. Clin Microbiol Rev 2011;24:14–28 .10.1128/CMR.00022-10 - DOI - PMC - PubMed
Cite

AltStyle によって変換されたページ (->オリジナル) /